Language selection

Search

Patent 2594768 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2594768
(54) English Title: GENERAL SOLVENT SYNTHESIS, PRODUCTION AND UTILITY
(54) French Title: SYNTHESE, PRODUCTION ET UTILISATION DE SOLVANTS GENERIQUES
Status: Deemed Abandoned and Beyond the Period of Reinstatement - Pending Response to Notice of Disregarded Communication
Bibliographic Data
(51) International Patent Classification (IPC):
  • C11D 07/00 (2006.01)
(72) Inventors :
  • ABDALLA, MAGD AHMED KOTB (Egypt)
(73) Owners :
  • MAGD AHMED KOTB ABDALLA
(71) Applicants :
  • MAGD AHMED KOTB ABDALLA (Egypt)
(74) Agent: LAVERY, DE BILLY, LLP
(74) Associate agent:
(45) Issued:
(86) PCT Filing Date: 2006-01-22
(87) Open to Public Inspection: 2006-07-27
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/EG2006/000004
(87) International Publication Number: EG2006000004
(85) National Entry: 2007-07-13

(30) Application Priority Data:
Application No. Country/Territory Date
2005010036 (Egypt) 2005-01-24

Abstracts

English Abstract


Published without an Abstract


French Abstract

Publié sans précis

Claims

Note: Claims are shown in the official language in which they were submitted.


7
Claims
I claim:
Manufacturing, producing, preparing and processing a mixture of
different combinations of anhydrous or aqueous or in any quantities or
molar volumes of the following soluble salts :
a- All salts of the alkali metals,
b- All salts of the ammonium ion NH4+,
c- All salts of nitrate ion (NO3-),
d- All salts of chlorate ion (ClO3-)
e- All salts of perchlorate ion (ClO4-),
f- All salts of acetate ion (C2H3O2-),
g- All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg22+),
h- All sulphates (SO4 2-) (except those of Ca2+, Sr2+, Ba2+ and Pb+),
i- Oxides of alkali metals, Ca2+, Sr2+, Ba2+ , and manganese
j- Carbonates (CO3 2-) of alkali metals, and ammonium salts,
k- Phosphates (PO4 3-) of alkali metals, and ammonium (NH4+) salts,
l- Sulfides (S2-) of alkali metals, and ammonium salts.
m- Any single or all and any combination of carbohydrates.
n- Any and all types of natural Honey.
Where:
1. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1"
are effective if used as "a", "b", "c", "d", "e", "f', "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general stain remover.
2. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general solvent for any purpose.
3. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k" are effective
if used as "a", "b", "c", "d", "e", "f', "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any

8
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general solvent for prevention of
human or animal tissue calcification.
4. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l",
are effective if used as "a", "b", "c", "d", "e", "f', "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general solvent for prevention of
human or animal tissue calculi in any system as renal calculi,
gall stones, gall sludge etc.,
5. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used. as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", as a general solvent for human or animal
tissue calcification.
6. All of "a", "b", "c", "d", "e", "f", "g", "h", "i",
are effective if used as "a", "b", "c", "d", "e", "f', "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", as a general solvent for human or animal
tissue calculi in any system as renal calculi, gall stones, gall
sludge etc.,
7. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions of convulsions and
epilepsy of any aetiology.
8. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "e", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions of osteoporosis of
any aetiology.
9. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to

9
"in" or "n" or "m+n", in medical conditions of bone resorption
of any aetiology.
10.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions of bone disease of
any aetiology.
11.All of "a", "b", "c", "d", "f", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added. to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions of cardiac
arrhythmias of any aetiology.
12.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions of loss of
transparency of eye lens, cornea, aqueous or vitreous body or
loss of transparency of any component of eye of any aetiology.
13.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "in" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions associated with
development of atheromatous plaques in any site of human or
animal body of any aetiology.
14.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "in+n", in medical conditions associated with
development of nervous system plaques in any site of human or
animal body of any aetiology.
15.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added , to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to

10
"m" or "n" or "m+n", in medical conditions associated with
impulse conduction defects in any site of human or animal body
of any aetiology.
16.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions associated with
need for glucoronization of any and all substances in need for
hepatic glucouronization.
17.All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "l"
are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i",
"j", "k", and "l" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "l" added to
"m" or "n" or "m+n", in medical conditions associated with
need for glucoronization of any and all drug overdose or
intoxication in need for hepatic glucouronization.

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 02594768 2007-07-13
WO 2006/076927 PCT/EG2006/000004
General solvent synthesis, production and utility
Technical Field:
1. Medicine
2. Chemistry
Background Art:
Detergents are formed of surface coinpounds which are not
enviromnentally safe. They are either natural or synthetic. Oil soluble
detergents are used in gasoline and lubricating oils to hold particulate
impurities in suspension. Among the water soluble detergents, alcohols and
common soaps are effective. Still more so are the synthetic types (syndets)
such as sulphonated dodecylbenzene and similar alkylates. The linear alkyl
sulphonates (LAS) are more biodegradable than are the branched-chain type;
they are made from petrochemicals by, various cracking and polymerization
techniques. Three general types of detergents are in use; anionic, cationic,
and non-ionic.
To overcome tissue metastatic calcification or stones developing in
various duct systems of human body as renal stones or gall bladder stones
shock wave lithotripsy is used, or surgically, or medicines to change ph of
urine to prevent further stone forination.
Calcium is essential for human and animal cells where it is essential
as an integral part of bone mineral, an integral part of the cell wall and its
biological function, the essential link *between excitation and contraction in
all forms of muscle, the essential link between excitation and secretion in
both endocrine and exocrine glands and an activator, regulator or inhibitor of
key enzymes.
Glucose is essential for absorption of other solutes. Depending on this
solute drag the preparation of any of -the mixtures described in this patent
includes glucose or a carbohydrate in different proportions.
Disclosure of Invention:
Solubility rules include; -All salts of the alkali metals are soluble, -
All salts of the ammonium ion NH4+ are soluble, - All salts of nitrate ion

CA 02594768 2007-07-13
WO 2006/076927 PCT/EG2006/000004
2
(N03") are soluble, - All salts of chlorate ion (C103") are soluble, - All
salts
of perchlorate ion (C104 ) are soluble, - All salts of acetate ion (C2H302 )
are
soluble, - All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg22+)
are soluble, - All sulphates (SO42-) (except those of Ca2+, Sr2+, Ba2+ and Pb)
are soluble, - All metal oxides .are insoluble, except those of alkali metals,
Ca2+, Sr2+, Ba2+ , - All carbonates (C032-) are insoluble, except those of
alkali metals, and airunonium salts, - All phosphates (P043") are insoluble,
except those of alkali metals, and aininonium (NH4+) salts, - All sulfides (Sa-
) are insoluble, except those of alkali metals, and ammonium salts.
The Novel Idea:
Using a mixture of different or any combinations of aqueous or
anhydrous or molar volumes of these soluble salts is capable of :
1. Stain removal.
2. Functioning as a general solvent for any purpose.
3. Functioning as a general solvent for human or animal tissue
calcification.
4. Functioning as a general solvent for human.or animal tissue calculi
in any system as renal calculi, gall stones, gall sludge etc.,
5.Delivering soluble calcium ions in medical conditions of
convulsions and epilepsy of any aetiology.
6.Delivering soluble sodium and potassium ions in medical conditions
of convulsions and epilepsy of any aetiology.
7.Delivering soluble calcium ions in medical conditions of
osteoporosis of any aetiology.
8.Delivering soluble calcium ions in medical conditions of bone
resorption of any aetiology.
9. Delivering soluble calcium ions in medical conditions of bone
disease of any aetiology.
10. Delivering soluble calcium ions in medical conditions of cardiac
arrhythmias of any aetiology.
11.Delivering soluble sodium and potassium ions in medical
conditions of cardiac arrhythmias of aiiy aetiology.
12. Delivering soluble ions in medical conditions of loss of
transparency of eye lens, cornea, aqueous or vitreous body or loss of
transparency of any component of eye of any aetiology.

CA 02594768 2007-07-13
WO 2006/076927 PCT/EG2006/000004
3
13. Delivering soluble ions in medical conditions associated with
development of atheromatous plaques in any site of human or animal body
of any aetiology.
14. Delivering soluble ions in medical conditions associated with
development of nervous system plaques in any site of human or animal body
of any aetiology.
15. Delivering soluble ions in medical conditions associated with
iinpulse conduction defects in any site of human or animal body of any
aetiology.
16. Providing oxidation - of aldoses to uronic acid and subsequent
glucoronization of all substances in need for hepatic glucouronization.
Detailed Description of the Requested Patent:
Manufacturing, producing, preparing and processing a mixture of
different combinations of anhydrous or aqueous or molar volumes of the
following soluble salts :
a- All salts of the alkali metals,
b- All salts of the ammonium ion NH4,
c- All salts of nitrate ion (N03-),
d- All salts of chlorate ion (C103 ),
e- All salts of perchlorate. ion (ClO4 ),
f- All salts of acetate ion (C2H302-),
g- All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg22+),
h- All sulphates (SO4'-) (except those of Ca2+, Sr2+, Ba2+ and Pb+),
i- Oxides of alkali metals, Ca2+, Sr2+, Ba2+, and Manganese
j- Carbonates (C032") of alkali metals, and ammoniuin salts,
k- Phosphates (P043") of alkali metals, and ammonium (NH4+) salts,
1- Sulfides (SZ ) of alkali metals, and aminoniuin salts.
m- Any single or all and any combination of carbohydrates.
n- Any and all types of natural Honey.
Where:
i. All of "a", LGb"' 4GC77' Ud77' GGe" ' GC.j,7 7' 44 95)' LLh~7' GGi))' GGjN'
~G7~ ' and LGl"
are effective if used as "a", "b"j, "c", "d", "e", "1 "gl'~', "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any

CA 02594768 2007-07-13
WO 2006/076927 PCT/EG2006/000004
4
combination of any or all entries of "a" through "1" added to
"in" or "n" or "in+n", as a general stain remover.
ii. All of "a", "b", ecC ~ GGd"' GGel? GG.~1)' GLgI!' LLh ' 4Cil7' LLj7!'
GGk7!' and CGl')
are effective if used as "a", "b", "c", Ged", "e", "17 "g", Leh", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"in" or "n" or "m+n", as a general solvent for any puipose.
iii. All of eea ' CGb"' K0 ' LLdN' GGe7)' LL~1 1 CGg)~' GGh~?' GLl7' LGjii'
Gik", and LG177
are effective if used as "a", "b", "c", 'id", eGe", "1', "g", "h", 'xi",
"j ", "k", and "1" added to "in" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general solvent for prevention of
human or animal tissue calcification.
iv. All of LLa"' GGb ' GLC77' GGd'7' GLe77' GG.~il ' GGg ' GGj7õ)?' 44i77'
LGj,f' GGk", and GGl"
are effective if used as "a", "b", "c", "d''j, "e" 417 "g", "h", "i",
"j ", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"in" or "n" or "m+n", as a general solvent for prevention of
human or animal tissue calculi in any system as renal calculi,
gall stones, gall sludge etc.,
v. All of GLa"' GGb" ' GGC77" GG,.777 ' LGe77' GG~' GGg)~' GGh ' GGi7f' GGj~7'
GGk)7, and GLl"
are effective if used a(s,~ "a", "b", "c", "d", "e", 461', "g", "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general solvent for human or animal
tissue calcification.
vi. All of LGa ' Gib"' iV)' GGd"' KC ' K,Q 5 ' LGg5)' GCh)7' GG7!' Kjl~' GLk",
and GGl"
are effective if used as "a", "b"1, "c", "d", "e", "1', "g", "h", "i",
"j", "k", and "1" added to "in" or "n" or "in+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", as a general solvent for human or animal
tissue calculi in any system as renal calculi, gall stones, gall
sludge etc.,
vii. A11 of GGa"' GGb77' 4LC77' Kd"' CLe57' CG,j.S)' GGg' GGh ' GGi7~' GGj77'
K7.~7~' and LL~7
are effective if used as "a", "b"j,, "c", "d", "e", "f', "gj'~', "h", "i",
"j", "k", and "1" added to "in" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions of convulsions and
epilepsy of any aetiology.

CA 02594768 2007-07-13
WO 2006/076927 PCT/EG2006/000004
viii. All of CGa)7' GLb))' LLC ' GGdl7' GGe7>' GGf !' LGg77' GGjjõ~~' GGi77'
GGj7!' LGk , and "1"
are effective if used as "a", "b", "c", "d",j "e", "f ', "g", "h", "i"
"j", "lc", and "1" added to "in" or "n" or "in+n" or as any
combination of any or all entries of "a" through "1" added to
"in" or "n" or "m+n", in medical conditions of osteoporosis of
any aetiology.
ix. All of GW?' GLb ' KC77' LLd"' GGe57' 4G.~71' GLgLLh3~' GGi ' iGjl~' GCk",
and CL77)
are effective if used as "a", "b"1, "c", "d", "e", "f', "g"i "h", "il",
"j", "k", and "1" added to "in" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"in" or "n" or "m+n", in medical conditions of bone resorption
of any aetiology.
x. All of Ka"' GLb"' GGC' LL,~ ~.]77' GGei7' LG.(.7 4G9 51 ' 4Gh ' GG77'
GGjl'1' GGk", and GGf!
are effective if used as "a", "b"l, "c", "d", "e", "1 ', "g", "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"in" or "n" or "m+n", in medical conditions of bone disease of
any aetiology.
xi. All of LGa"' LLbN' 6Gc55 ' GGd"' GV)' GL.~77' LLgI~' CGhYI' Ki7~' GGj7~'
GGk)', and GGl"
are effective if used as "a", "b1 "c", g",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
colnbination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions of cardiac
arrliythinias of any aetiology.
xii. Allof a , b , c ,. d , e I CT I g 1 h ~cei' j , k , and h,
are effective if used as "a", "b", "c", "d", "e", "f', "g", "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions of loss of
transparency of eye lens, cornea, aqueous or vitreous body or
loss of transparency of any coinponent of eye of any aetiology.
xiii. All of LLa"' GGb"' GGC7!' GCd"' GLe" ' GGf 4Gg75 ' 44h77' GGi ' GGj77'
GG7s77' and GG)7
are effective if used as "a", "b", "c", "d", "e" , "f', "gj'~', "h", "i",
"j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"in" or "n" or "m+n", in medical conditions associated with
development of atheromatous plaques in any site of human or
animal body of any aetiology.

CA 02594768 2007-07-13
WO 2006/076927 PCT/EG2006/000004
6
xiv. All of cea"' GGb"' GV)a GGd7)' Ke7!' GG~7? ' GGg7!' GGh7)' GGi72 ' LGjN'
GG7~~~' and CGl')
are effective if used as "a", "b"1, c'c", "d", "te", 64f ' "gl'~', Leh, eti",
"j"lc", and "1" added to "n1" or "n" or "m+n" or as any
coinbination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions associated with
development of nervous system plaques in any site of human or
animal body of any aetiology.
xv. All of Gia!!' CLbf)' CGC7!' iGd"' GGe)7' LG.~1 7' GGg51' GLh)~' iGi '
LLj77' CG1~i~7' and GG7N
are effective if used as "a", "b"1, eGc", "d", "e", "f', "gj'', "h", Geij",
"j", "k", and "1" added. to "m" or "n" or "m+n" or as any
coinbination of any or all entries of "a" through "1" added to
"in" or "n" or "in+n", in medical conditions associated with
impulse conduction defects in any site of human or animal body
of any aetiology.
xvi. All of GGa"' Ub77' CGc5!' LG~]77' GLel~' Kj~'17' GGg77' CLj7õ)~' GGi)f'
GGj~~' GG7~),' and Gi77
are effective if used. a(s,I "a", "b", "c" , "d''j, "e" , "f', "gj'~', "h",
"i",
"j", "k", and "1" added to "m" or "n" or "in+n" or as any
coinbination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions associated with
need for glucoronization of any and all substances in need for
hepatic glucouronization.
xvii. All of "a", "b", "c", "d", "e", "f', "g", "h", "i", "j", "k", and "1"
are effective if used as "a", "b", "c", "d", "e", "f', "g", "h", "i",
"j", "k", and "1" added " to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to
"m" or "n" or "in+n", in medical conditions associated with
need for glucoronization of any and all drug overdose or
intoxication in need for hepatic glucouronization.

Representative Drawing

Sorry, the representative drawing for patent document number 2594768 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Time Limit for Reversal Expired 2012-01-23
Application Not Reinstated by Deadline 2012-01-23
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2011-01-24
Inactive: Abandon-RFE+Late fee unpaid-Correspondence sent 2011-01-24
Inactive: Cover page published 2007-12-06
Inactive: Notice - National entry - No RFE 2007-12-04
Inactive: Inventor deleted 2007-12-04
Inactive: First IPC assigned 2007-08-23
Application Received - PCT 2007-08-22
National Entry Requirements Determined Compliant 2007-07-13
Application Published (Open to Public Inspection) 2006-07-27

Abandonment History

Abandonment Date Reason Reinstatement Date
2011-01-24

Maintenance Fee

The last payment was received on 2010-01-18

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Patent fees are adjusted on the 1st of January every year. The amounts above are the current amounts if received by December 31 of the current year.
Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Basic national fee - standard 2007-07-13
MF (application, 2nd anniv.) - standard 02 2008-01-22 2007-12-27
MF (application, 3rd anniv.) - standard 03 2009-01-22 2009-01-22
MF (application, 4th anniv.) - standard 04 2010-01-22 2010-01-18
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
MAGD AHMED KOTB ABDALLA
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 2013-01-23 1 3
Claims 2007-07-12 4 187
Description 2007-07-12 6 314
Reminder of maintenance fee due 2007-12-03 1 112
Notice of National Entry 2007-12-03 1 194
Reminder - Request for Examination 2010-09-22 1 118
Courtesy - Abandonment Letter (Maintenance Fee) 2011-03-20 1 174
Courtesy - Abandonment Letter (Request for Examination) 2011-05-01 1 165
PCT 2007-07-12 2 114
PCT 2007-08-21 2 109
Fees 2007-12-26 1 45
Fees 2009-01-21 1 46